The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Influence of Time of Day of Blood Pressure–Lowering Treatment on Cardiovascular Risk in Hypertensive Patients With Type 2 Diabetes
Open accessAbstract
OBJECTIVE: We prospectively investigated in hypertensive patients with type 2 diabetes if bedtime treatment with ≥1 hypertension medications exerts better blood pressure control and cardiovascular risk reduction than conventional therapy, in which all medications are ingested in the morning. RESEARCH DESIGN AND METHODS: We conducted a prospective, randomized, open-label, blinded end point trial on 448 hypertensive patients with type 2 diabetes, 255 men/193 women, mean ± SD age 62.5 ± 10.8 years, randomized to ingest all their prescribed hypertension medications upon awakening or ≥1 of them at bedtime. Ambulatory blood pressure was measured for 48 h at baseline and again annually or even more frequently (quarterly) after adjustments in treatment. RESULTS: After a median follow-up of 5.4 years, patients ingesting ≥1 hypertension medications at bedtime showed a significantly lower cardiovascular risk (adjusted by age and sex) than subjects ingesting all medications upon awakening (hazard ratio 0.33 [95% CI 0.21–0.54]; P < 0.001). The difference between groups in the adjusted risk of major events (cardiovascular death, myocardial infarction, and stroke) was also statistically significant (0.25 [0.10–0.61]; P = 0.003). Patients treated at bedtime showed significantly lower sleep time blood pressure mean and higher prevalence of controlled ambulatory blood pressure (62.5 vs. 50.9%; P = 0.013). There was a significant 12% cardiovascular risk reduction per each 5 mmHg decrease in asleep systolic blood pressure during follow-up (P < 0.001). CONCLUSIONS: Among patients with diabetes, treatment with ≥1 hypertension medications at bedtime, compared with all medications upon waking, resulted in improved ambulatory blood pressure control and significantly reduced cardiovascular morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although prior analyses of randomized clinical trials found a benefit to evening versus morning dosing of antihypertensive medications (81,82), these results have not been reproduced in subsequent trials.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [82]
In the citing paper
“Although prior analyses of randomized clinical trials found a bene fi t to evening versus morning dosing of antihypertensive medications (74,75), these results have not been reproduced in subsequent trials.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [75]
In the citing paper
“These results were replicated in people with type II diabetes (181).”
From Role of the circadian system in cardiovascular disease (2018) · cites this paper as [181]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · cited 1×
“We thus conclude that the actual controversy on the possible J-shaped relation with CVD risk, described so far only for clinic blood pressure determined in patients presumably treated in the morning (21,22), might not apply (when avoiding nocturnal hypotension) to asleep blood pressure mean, a more significant predict…”
BackgroundDolan, E., Stanton, A., Thijs, L., Hinedi, K., Atkins, N., McClory, S., Hond, E. D., McCormack, P., Staessen, J. A., & O’Brien, E. (2005) · Hypertension · doi:10.1161/01.hyp.0000170138.56903.7a · Cited by 1,227
Ohkubo, T., Hozawa, A., Yamaguchi, J., Kikuya, M., Ohmori, K., Michimata, M., Matsubara, M., Hashimoto, J., Hoshi, H., Araki, T., et al. (2002) · Journal of Hypertension · doi:10.1097/00004872-200211000-00017 · Cited by 1,053
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study
Boggia, J., Li, Y., Thijs, L., Hansen, T. W., Kikuya, M., Björklund-Bodegård, K., Richart, T., Ohkubo, T., Kuznetsova, T., Torp-Pedersen, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61538-4 · Cited by 887
Fagard, R. H., Celis, H., Thijs, L., Staessen, J. A., Clement, D. L., De Buyzere, M. L., & De Bacquer, D. A. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.100727 · Cited by 742
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2010) · Chronobiology International · doi:10.3109/07420528.2010.510230 · Cited by 608 · cited 1×
“The MAPEC (Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares [Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular Events]) study was specifically designed to investigate prospectively whether bedtime treatment with $1 hypertension medications exerts significantly better blood pre…”
BackgroundSelf-citation
Cited by
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“4 years if at least one antihypertensive medication was given at bedtime (345).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“4 years if at least one antihypertensive medication was given at bedtime (277).”
BackgroundStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
“4 years if at least one antihypertensive medication was given at bedtime (243).”
BackgroundThe Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
“over 24 h is high, the time of administration may be tentatively changed from morning to evening, the dose split into morning and evening or an additional dose taken in the evening or before going to bed [688, 689].”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
“In two subgroupanalyses of a single subsequent randomized clinical trial, moving at least one antihypertensive medication to bedtime significantly reduced cardiovascular events, but results were based on small numbers of events (90,91).”
BackgroundTreatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
“Additionally, prescribing one or more hypertension medications to be taken at bedtime may have additional CVD benefits (190).”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
“medication tobedtimesignificantly reduced cardiovascular events, but results were based on a small number of events (68).”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
“In two subgroup analyses of a single subsequent randomized controlled trial, moving at least one antihypertensive medication to bedtime significantly reduced cardiovascular events, but results were based on a small number of events (64).”
Background9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 485
“In two subgroup analyses of a single subsequent randomized controlled trial, moving at least one antihypertensive medication to bedtime significantly reduced cardiovascular events, but results were based on a small number of events (36).”
Background10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Role of the circadian system in cardiovascular disease
Thosar, S. S., Butler, M. P., & Shea, S. A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci80590 · Cited by 443
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 486
8. Cardiovascular Disease and Risk Management
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s011 · Cited by 329
“one antihypertensive medication was given at bedtime (26).”
BackgroundCircadian Rhythm Connections to Oxidative Stress: Implications for Human Health
Wilking, M., Ndiaye, M., Mukhtar, H., & Ahmad, N. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4889 · Cited by 318
“As mentioned earlier, the knowledge that blood pressure and other cardiovascular events follow a circadian rhythm has also been exploited in therapeutics for best response, when giving certain medications, especially angiotensin receptor blockers and other antihypertensive drugs (72, 104, 192).”
BackgroundSpallone, V. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0259 · Cited by 295
Circadian mechanisms of 24-hour blood pressure regulation and patterning
Smolensky, M. H., Hermida, R. C., & Portaluppi, F. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.02.003 · Cited by 237
Self-citation8. Cardiovascular Disease and Risk Management
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s011 · Cited by 233
9. Cardiovascular Disease and Risk Management
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s012 · Cited by 223
“4 years if at least one antihypertensive medication was given at bedtime (38).”
BackgroundChronotherapy With Low-Dose Aspirin for Prevention of Complications in Pregnancy
Ayala, D. E., Ucieda, R., & Hermida, R. C. (2013) · Chronobiology International · doi:10.3109/07420528.2012.717455 · Cited by 203
“…recently documented that the progressive reduction in asleep BP mean, a novel therapeutic target best achieved with bedtime hypertension therapy (Hermida et al., 2011a, 2013b; Portaluppi & Smolensky, 2010; Smolensky et al., 2010), is the most significant predictor of cardiovascular event-free…”
BackgroundInfluentialSelf-citationHermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2013) · Chronobiology International · doi:10.3109/07420528.2012.701127 · Cited by 203
“As previously reported (Hermida et al., 2011b, 2013a), analyses based on a single ABPM profile only from each subject obtained either at baseline, as customary in all previous studies on this topic, or at the last evaluation after a median follow-up time of 5.6 yrs, indicate that among several…”
BackgroundMethodResultInfluentialSelf-citationHermida, R. C., Smolensky, M. H., Ayala, D. E., Portaluppi, F., Crespo, J. J., Fabbian, F., Haus, E., Manfredini, R., Mojón, A., Moyá, A., et al. (2013) · Chronobiology International · doi:10.3109/07420528.2013.750490 · Cited by 202
“…(e.g., Ayala & Hermida, 2013; Clement et al., 2003; Dolan et al., 2005; Eguchi et al., 2008; Hansen et al., 2007; Hermida & Ayala, 2002, 2004, 2010; Hermida et al., 2011c, 2012a, 2012b, 2013b; Minutolo et al., 2011; Perloff et al., 1983; Salles et al., 2008; Staessen et al., 1999; Verdecchia et…”
InfluentialSelf-citationSmolensky, M. H., Hermida, R. C., Reinberg, A., Sackett-Lundeen, L., & Portaluppi, F. (2016) · Chronobiology International · doi:10.1080/07420528.2016.1184678 · Cited by 197
“…BP during the 5.6 yearmedian follow-up of theMAPEC trial reveal 17% reduction in vascular risk per 5 mmHg decrease in asleep SBPmean (p 0.001), by far best achieved with the bedtime chronotherapeutic approach, independent of change in any other ABPM-derived parameter (Hermida et al., 2011a).”
BackgroundMethodResultInfluentialSelf-citationManagement of Hypertension in CKD: Beyond the Guidelines
Judd, E., & Calhoun, D. A. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.12.001 · Cited by 158
Mojón, A., Ayala, D. E., Piñeiro, L., Otero, A., Crespo, J. J., Moyá, A., Bóveda, J., de Lis, J. P., Fernández, J. R., Hermida, R. C., et al. (2012) · Chronobiology International · doi:10.3109/07420528.2012.703083 · Cited by 159
“…in the asleep BP mean, a novel therapeutic target best achieved with bedtime therapy with ≥1 hypertension medications (Hermida & Smolensky, 2004; Hermida et al., 2005, 2007a, 2010a, 2011a, 2011e, 2013b, 2013e; Portaluppi & Smolensky, 2010; Smolensky et al., 2010, 2012), is themost…”
BackgroundMethodResultInfluentialSelf-citationDiabetes and Hypertension: A Comparative Review of Current Guidelines
Cryer, M., Horani, T., & DiPette, D. J. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12638 · Cited by 158
“was significant reduction in CVD risk as well as improved nocturnal BP reduction when at least one antihypertensive agent was given at bedtime.(19) Thus, the approach to nocturnal hypertension is another area for consideration in future guideline development.”
BackgroundWang, T., Tan, R., Lee, H., Ihm, S., Rhee, M., Tomlinson, B., Pal, P., Yang, F., Hirschhorn, E., PRESCOTT, M. F., et al. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.08484 · Cited by 145
Ambulatory Blood Pressure Monitoring in the Diagnosis and Management of Hypertension
Grossman, E. (2013) · Diabetes Care · doi:10.2337/dcs13-2039 · Cited by 157
“Recently, it has been suggested that administration of at least one antihypertension agent at bedtime may improve BP control (47).”
BackgroundChronotherapy for Hypertension
Bowles, N. P., Thosar, S. S., Herzig, M. X., & Shea, S. A. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0897-4 · Cited by 141
Ayala, D. E., Moyá, A., Crespo, J. J., Castiñeira, C., Domínguez-Sardiña, M., Gomara, S. M., Sineiro, E., Mojón, A., Fontao, M. J., & Hermida, R. C. (2012) · Chronobiology International · doi:10.3109/07420528.2012.701489 · Cited by 136
“…the asleep BP mean is a better predictor of CVD events than the awake or 24-h BP mean (Astrup et al., 2007; Ben-Dov et al., 2007; Boggia et al., 2007; Bouhanick et al., 2008; Dolan et al., 2005; Hermida et al., 2011b, 2012, 2013a, 2013d; Fagard et al., 2008; Fan et al., 2010; Kikuya et al., 2005).”
BackgroundMethodResultInfluentialSelf-citationHermida, R. C., Ayala, D. E., Fernández, J. R., Mojón, A., Smolensky, M. H., Fabbian, F., & Portaluppi, F. (2012) · Chronobiology International · doi:10.3109/07420528.2012.709448 · Cited by 124
“…more normal dipping pattern—two new and novel therapeutic targets requiring proper patient evaluation by ABPM —were best achieved with bedtime therapy of ≥1 medications, and they were the most significant predictors of event-free survival (Hermida et al., 2010c, 2011b, 2011c, 2011d, 2012a, 2013b).”
BackgroundMethodInfluentialSelf-citationHermida, R. C., Ayala, D. E., Smolensky, M. H., Fernández, J. R., Mojón, A., & Portaluppi, F. (2015) · Hypertension Research · doi:10.1038/hr.2015.142 · Cited by 127
Self-citationHermida, R. C., Ayala, D. E., Fernández, J. R., & Mojón, A. (2012) · Chronobiology International · doi:10.3109/07420528.2012.702581 · Cited by 103
“…to avert nocturnal hypotension (Hermida et al., 2002b), especially with the bedtime-treatment regimen because of previous studies demonstrating its strong effects on the asleep SBP and DBP means (Hermida & Smolensky, 2004; Hermida et al., 2005, 2007a, 2011a, 2013a; Smolensky et al., 2010, 2012).”
BackgroundResultInfluentialSelf-citationHermida, R. C., Ayala, D. E., Fontao, M. J., Mojón, A., & Fernández, J. R. (2012) · Chronobiology International · doi:10.3109/07420528.2012.701457 · Cited by 97
“…especially according to administration-time (morning vs. evening) treatment regimen as a cost-effective means of better preventing CVD events (Hermida et al., 2010, 2011b, 2011c, 2011d, 2013a; Manfredini et al., 1996a, 1996b, 1999a, 1999b, 2004; Pinotti et al., 2005; Portaluppi & Hermida,…”
BackgroundMethodInfluentialSelf-citationTiming is important in medication administration: a timely review of chronotherapy research
Kaur, G., Phillips, C. L., WONG, K. K. H., & Saini, B. (2013) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9749-0 · Cited by 98
“[71] Spain Hypertensive patients with type-2 diabetic.”
Ayala, D. E., Hermida, R. C., Mojón, A., & Fernández, J. R. (2013) · Chronobiology International · doi:10.3109/07420528.2012.701455 · Cited by 87
“…have found that the sleeptime BP mean is a better predictor of CVD events than the awake or 24-h BP mean (Ben-Dov et al., 2007; Boggia et al., 2007; Bouhanick et al., 2008; Dolan et al., 2005; Fagard et al., 2008; Fan et al., 2010; Hermida et al., 2011b, 2012a, 2013a, 2013e; Kikuya et al., 2005).”
BackgroundInfluentialSelf-citationEstimating blood pressure trends and the nocturnal dip from photoplethysmography
Radha, M., de Groot, K., Rajani, N. B., Wong, C. C. P., Kobold, N., Vos, V., Fonseca, P. M., Mastellos, N., Wark, P. A., Velthoven, N., et al. (2019) · Physiological Measurement · doi:10.1088/1361-6579/ab030e · Cited by 97
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.231 · Cited by 80
Self-citationSleep-Time Blood Pressure and the Prognostic Value of Isolated-Office and Masked Hypertension
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.208 · Cited by 76
Self-citationBlood Pressure Variability and Autonomic Dysfunction
Spallone, V. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1108-z · Cited by 85
Hermida, R. C., Smolensky, M. H., Ayala, D. E., & Portaluppi, F. (2015) · Chronobiology International · doi:10.3109/07420528.2015.1113804 · Cited by 89
“…of sleep-time relative BP decline towards the normal dipper profile, by BP-lowering medications of six different classes are greatly improved when consistently ingested at bedtime than upon awakening (Hermida et al., 2007a, 2011a, 2013c, j,k, 2014c, d, 2015b; Smolensky et al., 2010, 2012, 2015b).”
BackgroundMethodResultInfluentialSelf-citationStergiou, G. S., Brunström, M., MacDonald, T. M., Kyriakoulis, K. G., Bursztyn, M., Khan, N. A., Bakris, G. L., Κόλλιας, Α., Menti, A., Muntner, P., et al. (2022) · Journal of Hypertension · doi:10.1097/hjh.0000000000003240 · Cited by 79
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2012) · Chronobiology International · doi:10.3109/07420528.2012.701534 · Cited by 70
“…ingested at bedtime might be related to their significantly greater reduction of the asleep SBP and DBP means plus increase of the sleep-time relative BP decline towards the more normal dipper pattern associated with lower CVD risk than when ingested upon awakening (Hermida et al., 2011b, 2013a).”
BackgroundInfluentialSelf-citationHermida, R. C., Ayala, D. E., Mojón, A., Fontao, M. J., Chayán, L., & Fernández, J. R. (2012) · Chronobiology International · doi:10.3109/07420528.2012.701487 · Cited by 70
“…the diagnosis of hypertension, i.e., identification of persons at elevated CVD risk who could benefit from BP-lowering treatment, should preferably be based not just on a potentially elevated clinic or even ABPM-derived awake BP, but mainly on asleep BP (Hermida et al., 2011c, 2012a, 2012b, 2013a).”
BackgroundMethodResultInfluentialSelf-citationRorie, D. A., Rogers, A., Mackenzie, I. S., Ford, I., Webb, D. J., Willams, B., Brown, M. J., Poulter, N. R., Findlay, E. A., Saywood, W., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010313 · Cited by 68
“There is also evidence to suggest that antihypertensive drugs taken in the evening rather than in the morning reduce nocturnal blood pressure to a greater extent, and might have more benefit in hypertension alone(8) 9 hypertension with renal disease(10) 11 and hypertension with diabetes.(12) A recent study that examin…”
BackgroundHermida, R. C., Ayala, D. E., Fernández, J. R., Mojón, A., & Smolensky, M. H. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12909 · Cited by 69
“Practical recommendations for routine incorporation of ABPM into clinical medicine for diagnosis of hypertension, assessment of CVD risk and attainment of therapeutic goals in adults have already been provided16; they include the following: (i) clinical application of ABPM to adults (≥18 years of age) of the general p…”
BackgroundMethodResultInfluentialSelf-citationTiming of food intake: Sounding the alarm about metabolic impairments? A systematic review
Beccuti, G., Monagheddu, C., Evangelista, A., Ciccone, G., Broglio, F., Soldati, L., & Bo, S. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.005 · Cited by 64
Crespo, J. J., Piñeiro, L., Otero, A., Castiñeira, C., Ríos, M. T. P., Regueiro, A., Mojón, A., Lorenzo, S., Ayala, D. E., Hermida, R. C., et al. (2012) · Chronobiology International · doi:10.3109/07420528.2012.701459 · Cited by 68
“…hypertension are common in patients with CKD (Agarwal & Andersen, 2005; Agarwal et al., 2009; Davidson et al., 2006; Mojón et al., 2013; Pogue et al., 2009; Portaluppi et al., 1990), leading to the proposed recommendation of bedtime hypertension treatment for these patients (Hermida et al., 2011d).”
BackgroundResultInfluentialSelf-citationHermida, R. C., Ayala, D. E., Mojón, A., Fontao, M. J., & Fernández, J. R. (2011) · Chronobiology International · doi:10.3109/07420528.2011.589935 · Cited by 64
“Clinical studies have consistently documented administration-time differences in BP-lowering efficacy, duration of action, and effects on the circadian BP pattern by medications interacting with the renin-angiotensinaldosterone system (Hermida et al., 2011a; Smolensky et al., 2010).”
BackgroundInfluentialSelf-citationHermida, R. C., Ayala, D. E., Smolensky, M. H., Fernández, J. R., Mojón, A., & Portaluppi, F. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.04.001 · Cited by 75
Self-citationChronotherapy improves blood pressure control and reduces vascular risk in CKD
Hermida, R. C., Ayala, D. E., Smolensky, M. H., Mojón, A., Fernández, J. R., Crespo, J. J., Moyá, A., Ríos, M. T. P., & Portaluppi, F. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.79 · Cited by 70
Self-citationAmbulatory Blood Pressure in Chronic Kidney Disease: Ready for Prime Time?
Velasquez, M. T., Beddhu, S., Nobakht, E., Rahman, M., & Raj, D. S. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.05.001 · Cited by 62
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2015) · Diabetologia · doi:10.1007/s00125-015-3749-7 · Cited by 63
“therapy, significantly better reduction of CVD risk [21], also in high-risk patients with diabetes [22], chronic kidney disease (CKD) [23], or resistant hypertension [24].”
BackgroundSelf-citationTargeting Nocturnal Hypertension in Type 2 Diabetes Mellitus
Rossen, N. B., Knudsen, S. T., Fleischer, J., Hvas, A., Ebbehøj, E., Poulsen, P. L., & Hansen, K. W. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03958 · Cited by 57
Pathophysiological Links Between Diabetes and Blood Pressure
Libianto, R., Batu, D., MacIsaac, R. J., Cooper, M. E., & Ekinci, E. I. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.010 · Cited by 67
Hermida, R. C. (2016) · Chronobiology International · doi:10.1080/07420528.2016.1181078 · Cited by 54
“…(MAPEC, i.e. Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular Events) discussed below (Ayala et al., 2013a; Hermida, 2007; Hermida et al., 2010c, 2011b, 2011c, 2011d, 2012a, 2012b, 2013b, 2013e, 2013f, 2013g, 2013h, 2013i, 2016a, 2016b), relied upon only a single,…”
BackgroundMethodResultInfluentialSelf-citationThe role of circadian clocks in metabolic disease.
Li, M., Li, C.-M., & Wang, Z. (2012) · PubMed Central · Cited by 67
Carter, B. L., Chrischilles, E. A., Rosenthal, G., Gryzlak, B. M., Eisenstein, E. L., & Weg, M. W. V. (2013) · Journal of Clinical Hypertension · doi:10.1111/jch.12238 · Cited by 53
“The ADA recommendation received an “A” rating, which was somewhat surprising since it was based on one relatively small trial in patients with diabetes (see below).(7) It is commonly thought that drug absorption, distribution, and elimination are constant processes in a given individual.”
BackgroundMethodCircadian Variation in Efficacy of Medications
Walton, J. C., Walker, W. H., Bumgarner, J. R., Meléndez‐Fernández, O. H., Liu, J. A., Hughes, H. L., Kaper, A. L., & Nelson, R. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2073 · Cited by 55
“For treatment of hypertension in patients with T2DM, evening administration of antihypertensive agents was similarly reported to be most effective at BP control compared with morning dosing.(60,71,72) Very few studies have focused on the circadian differences in the effectiveness of antihypertensives in patients with…”
BackgroundBooth, J. N., Muntner, P., Abdalla, M., Diaz, K. M., Viera, A. J., Reynolds, K., Schwartz, J. E., & Shimbo, D. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000791 · Cited by 53
“Although actigraphy has been used in prior ABPM studies, scarce data exist on the associations of night-time ABP parameters with outcomes using this method to define the night-time period [27,28].”
MethodTherapeutics on the clock: Circadian medicine in the treatment of chronic inflammatory diseases
Jacob, H., Curtis, A. M., & Kearney, C. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114254 · Cited by 57
Treatment of Hypertension With Chronotherapy: Is It Time of Drug Administration?
Stranges, P. M., Drew, A. M., Rafferty, P., Shuster, J. E., & Brooks, A. D. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014563535 · Cited by 58
“Chronotherapy has been shown to improve CV risk and 24-hour BP profile parameters in patients with CKD.”
BackgroundInfluentialHermida, R. C., Ríos, M. T., Crespo, J. J., Moyá, A., Domínguez-Sardiña, M., Otero, A., Sánchez, J. J., Mojón, A., Fernández, J. R., Ayala, D. E., et al. (2013) · Chronobiology International · doi:10.3109/07420528.2012.701460 · Cited by 48
“…in end-organ injury and CVD events (Astrup et al., 2007; Boggia et al., 2007; Brotman et al., 2008; Dolan et al., 2005; Eguchi et al., 2008; Hermida et al., 2003, 2011b, 2012a, 2013a, 2013e, 2013f; Manfredini et al., 2004; Nakano et al., 1998; Ohkubo et al., 2002; Portaluppi & Lemmer,…”
BackgroundResultInfluentialSelf-citationAssociation of Systemic Medication Use with Glaucoma and Intraocular Pressure
Vergroesen, J. E., Schuster, A. K.-G., Stuart, K. V., Asefa, N. G., Cougnard‐Grégoire, A., Delcourt, C., Schweitzer, C., Barreto, P., Coimbra, R., Foster, P. J., et al. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.05.001 · Cited by 51
Hermida, R. C., Ayala, D. E., Crespo, J. J., Mojón, A., Chayán, L., Fontao, M. J., & Fernández, J. R. (2012) · Chronobiology International · doi:10.3109/07420528.2012.701131 · Cited by 48
“…(Hermida et al., 2002d), especially in patients under a bedtime-treatment Chronobiology International regimen because of previous studies demonstrating its strong effects on the asleep SBP and DBP means (Hermida & Smolensky, 2004; Hermida et al., 2005, 2007a, 2011a, 2013b; Smolensky et al., 2010).”
BackgroundMethodResultInfluentialSelf-citationAmbulatory Blood Pressure Monitoring for the Early Identification of Hypertension in Pregnancy
Ayala, D. E., & Hermida, R. C. (2012) · Chronobiology International · doi:10.3109/07420528.2012.714687 · Cited by 56
“…increased incidence of fatal and nonfatal cardiovascular events (Astrup et al., 2007; Boggia et al., 2007; Brotman et al., 2008; Dolan et al., 2005; Hermida et al., 2011a, 2013a, 2013c; Ingelsson et al., 2006; Kario et al., 2001; Nakano et al., 1998; Ohkubo et al., 2002; Sturrock et al., 2000;…”
BackgroundInfluentialSelf-citationRíos, M. T. P., Domínguez-Sardiña, M., Ayala, D. E., Gomara, S. M., Sineiro, E., Pousa, L., Callejas, P. A., Fontao, M. J., Fernández, J. R., & Hermida, R. C. (2012) · Chronobiology International · doi:10.3109/07420528.2012.701135 · Cited by 52
“…true RH, implicit in the classification criteria used in this report, there were no significant differences between groups in asleep SBP and DBP means, a more relevant prognostic marker of CVD risk (Hermida et al., 2011b, 2012a, 2012b, 2013a; Portaluppi & Smolensky, 2010; Portaluppi et al., 2012).”
BackgroundMethodResultInfluentialSelf-citationMoyá, A., Crespo, J. J., Ayala, D. E., Ríos, M. T. P., Pousa, L., Callejas, P. A., Salgado, J. L., Mojón, A., Fernández, J. R., Hermida, R. C., et al. (2012) · Chronobiology International · doi:10.3109/07420528.2012.702587 · Cited by 45
“…(Ayala et al., 2013a; Ben-Dov et al., 2007; Boggia et al., 2007; Dolan et al., 2005; Fagard et al., 2008; Fan et al., 2010; Hermida et al., 2011b, 2013d; Kikuya et al., 2005), especially in patients with type 2 diabetes (Astrup et al., 2007; Bouhanick et al., 2008; Hermida et al., 2011c, 2012).”
BackgroundResultInfluentialSelf-citationCardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 44
“Interestingly, taking ≥1 antihypertensive drugs at bedtime improved ambulatory BP control and prevented new-onset T2DM in hypertensive patients [201], whereas it decreased ambulatory BP as well as CVD morbidity and mortality in T2DM patients [202].”
BackgroundMaqsood, M. H., Messerli, F. H., Skolnick, A. H., Newman, J. D., Berger, J. S., & Bangalore, S. (2023) · Hypertension · doi:10.1161/hypertensionaha.122.20862 · Cited by 41
Salles, G. F., Leite, N. C., Pereira, B. D. B., do Nascimento, E. M., & Cardoso, C. R. L. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328364103f · Cited by 42
“A recent randomized clinical trial of bedtime antihypertensive drug intake [41] also supported the efficacy of a lower night-time SBP (<110 mmHg) to reduce cardiovascular risk.”
BackgroundRahman, A., Hasan, A. U., Nishiyama, A., & Kobori, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020400 · Cited by 43
“In a prospective, randomized, open-label, blinded end point trial in 448 hypertensive patients with T2D, Hermida et al. (2011) demonstrated that antihypertensive medications taken at bedtime produced a significantly lower CV risk and decreased the adjusted risk of CV death, myocardial infarction, and stroke [130].”
BackgroundInfluentialBurnier, M., Kreutz, R. H., Narkiewicz, K., Kjeldsen, S. E., Oparil, S., & Mancia, G. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002532 · Cited by 49
“After the initial publication of the MAPEC study, additional articles were published using the same database in subgroups of patients with diabetes [87] and CKD [88], with similar incredible adjusted RR reductions (hazard ratios of 0.”
MethodHermida, R. C., Smolensky, M. H., Balan, H., Castriotta, R. J., Crespo, J. J., Dagan, Y., El‐Toukhy, S., Fernández, J. R., FitzGerald, G. A., Fujimura, A., et al. (2020) · Chronobiology International · doi:10.1080/07420528.2020.1850468 · Cited by 40
“…prognostic markers of CVD risk and thus novel therapeutic targets for meaningful advances in CVD prevention and prolongation of patient CVD event-free survival (Hermida et al. 2011a, 2018), thereby warranting them as primary ABP endpoints in hypertension chronopharmacology and chronotherapy trials.”
BackgroundMethodInfluentialSelf-citationSleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction
Hermida, R. C., Ayala, D. E., Mojón, A., Smolensky, M. H., Portaluppi, F., & Fernández, J. R. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2014.1 · Cited by 40
Self-citationThe importance of night-time systolic blood pressure in diabetic patients: Dublin Outcome Study
Draman, M. S., Dolan, E., Poel, L. V. D., Tun, T. K., McDermott, J. H., Sreenan, S., & O'Brien, E. T. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000576 · Cited by 38
“[21], in a randomized open-label trial, have shown that dosing antihypertensive medication at night-time leads to greater nocturnal reductions in SBP and markedly improved CVD outcomes as compared to the morning.”
BackgroundHypertension and Chronic Kidney Disease Progression: Why the Suboptimal Outcomes?
BIDANI, A. K., Griffin, K. A., & Epstein, M. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.008 · Cited by 35
Clinical features and therapeutic perspectives on hypertension in diabetics
Katayama, S., Hatano, M., & Issiki, M. (2018) · Hypertension Research · doi:10.1038/s41440-017-0001-5 · Cited by 39
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2012) · Chronobiology International · doi:10.3109/07420528.2012.701885 · Cited by 35
“In this regard, we recently documented that the progressive reduction of the asleep BP mean, a novel therapeutic target best achieved with bedtime hypertension therapy, is themost significant predictorofCVDevent-free survival (Hermida et al., 2010b, 2011b, 2012a, 2012b, 2013a, 2013d).”
BackgroundInfluentialSelf-citationImpaired nocturnal blood pressure dipping in patients with type 2 diabetes mellitus
Kim, Y.-S., Davis, S. C. A. T., Stok, W. J., van Ittersum, F. J., & LIESHOUT, J. J. V. (2018) · Hypertension Research · doi:10.1038/s41440-018-0130-5 · Cited by 33
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2015) · Diabetologia · doi:10.1007/s00125-015-3806-2 · Cited by 33
Self-citationSleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2015) · Diabetologia · doi:10.1007/s00125-015-3748-8 · Cited by 36
“Inclusion and exclusion criteria Complete details of the rationale and design of the MAPEC study are described in previous publications [5, 6, 11, 12, 20–22, 30].”
BackgroundMethodInfluentialSelf-citationHermida, R. C., Ayala, D. E., Smolensky, M. H., Fernández, J. R., Mojón, A., Crespo, J. J., Ríos, M. T. P., Moyá, A., & Portaluppi, F. (2014) · Current Hypertension Reports · doi:10.1007/s11906-013-0412-x · Cited by 34
Self-citationSerinel, Y., Yee, B. J., Grunstein, R. R., WONG, K. K. H., Cistulli, P. A., Arima, H., & Phillips, C. L. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-209504 · Cited by 36
Resistant Hypertension: Concepts and Approach to Management
Sander, G. E., & Giles, T. D. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0226-7 · Cited by 31
Yanagi, M., Tamura, K., Fujikawa, T., Wakui, H., Kanaoka, T., Ohsawa, M., Azushima, K., Maeda, A., Kobori, H., & Umemura, S. (2012) · Hypertension Research · doi:10.1038/hr.2012.184 · Cited by 29
Hermida, R. C., Smolensky, M. H., Ayala, D. E., Fernández, J. R., Moya, A., Crespo, J. J., Mojón, A., Ríos, M. T. P., Fabbian, F., & Portaluppi, F. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft285 · Cited by 31
“The MAPEC Study results not only substantiate that the asleep SBP mean is the most significant prognostic marker of CVD morbidity and mortality, as previously suggested [6, 7, 11, 15–18], but they also document for the first time that reduction of the asleep SBP mean by properly timed hypertension therapy significantl…”
ResultSelf-citationHjortkjær, H. Ø., Jensen, T. J., Kofoed, K. F., Mogensen, U. M., Sigvardsen, P. E., Køber, L., Hilsted, K. L., Corinth, H., Theilade, S., & Hilsted, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012307 · Cited by 27
“Strengths and weaknesses in relation to other studies: Most other similar studies are non-blinded with the risk of bias and only examine type 2 diabetes.(10) 18 This is the first study measuring dipping and BD in type 1 diabetes.”
BackgroundResultSobiczewski, W., Wirtwein, M., Gruchała, M., & Kocić, I. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2013.12.009 · Cited by 27
“…Gdańsk, Poland b Department of Pharmacology, Medical University of Gdansk, Gdansk, Poland A R T I C L E I N F O Article history: Received 10 August 2013 Received in revised form 30 November 2013 Accepted 16 December 2013 Available online 2 April 2014 Keywords: Hypertension…”
BackgroundOptimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU
Brothwell, S., Dutton, M., Ferro, C. J., Stringer, S. J., & Cockwell, P. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-218 · Cited by 26
“Blunted sleep-time decline has been associated with an increased incidence of cardiovascular disease in CKD and other settings [35-51]; this has important implications for the management of BP in people with CKD [35,36,40,45,46,62-76].”
BackgroundManaging Hypertension with Ambulatory Blood Pressure Monitoring
White, W. B., & Gulati, V. (2015) · Current Cardiology Reports · doi:10.1007/s11886-014-0556-6 · Cited by 25
Bedtime Blood Pressure Chronotherapy Significantly Improves Hypertension Management
Hermida, R. C., Ayala, D. E., Fernández, J. R., Mojón, A., Crespo, J. J., Ríos, M. T. P., & Smolensky, M. H. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.05.010 · Cited by 25
Self-citationVinik, A. I., Camacho, P. M., Davidson, J. A., Handelsman, Y., Lando, H. M., Leddy, A. L., Reddy, S. K., Cook, R., Spallone, V., Tesfaye, S. H., et al. (2017) · Endocrine Practice · doi:10.4158/ep-2017-0053 · Cited by 27
Hermida, R. C., Hermida‐Ayala, R. G., Smolensky, M. H., Mojón, A., & Fernández, J. R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1825681 · Cited by 23
Self-citationHjortkjær, H. Ø., Persson, F., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S., & Rossing, P. R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108270 · Cited by 28
Blood Pressure Variability and Its Management in Hypertensive Patients
Choi, H.-J. (2012) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2012.33.6.330 · Cited by 23
Rahelić, D., Javor, E., Lucijanić, T., & Skelin, M. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1226514 · Cited by 26
Sabio, J. M., Martínez-Bordonado, J., Sánchez‐Berná, I., Vargas‐Hitos, J. A., Mediavilla, J. D., Navarrete‐Navarrete, N., Zamora‐Pasadas, M., Ruíz, M. E., & Jiménez-Alonso, J. F. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.150531 · Cited by 22
Metadata
- Authors
- Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R.
- Affiliations
- Universidade de Vigo (ES)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-05-20
- Volume
- 34
- Issue
- 6
- Pages
- 1270-1276
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3114338
- OpenAlex
- W2141454310
- Cited by
- 213
- References
- 25
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 9 · 2022: 9 · 2021: 3 · 2020: 10 · 2019: 10 · 2018: 16 · 2017: 15 · 2016: 21 · 2015: 27 · 2014: 14 · 2013: 16 · 2012: 36
- FWCI
- 16.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- antihypertensive drugs, type 2 diabetes, hypertension, ambulatory blood pressure, nocturnal blood pressure, cardiovascular risk reduction, cardiovascular mortality, myocardial infarction, stroke, blood pressure control
- MeSH terms
- Adolescent, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Circadian Rhythm, Diabetes Mellitus, Type 2, Female, Humans, Hypertension, Male, Middle Aged, Risk, Blood Pressure Monitoring, Ambulatory, Drug Chronotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.